Overview

Cannabinoids for Behavioral Problems in Children With ASD

Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the safety, tolerability and efficacy of cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio, BOL Pharma, Israel] for behavioral problems in children and youth with ASD.
Phase:
Phase 2
Details
Lead Sponsor:
Shaare Zedek Medical Center
Treatments:
Dronabinol